Kiobrina(TM) shows positive phase II results in preterm infants

Stockholm, Sweden - November 25, 2009 - Biovitrum AB (STO: BVT) today
announced that the first of two clinical phase II studies, designed
to together show proof of concept of Kiobrina(TM) (rhBSSL) in preterm
infants, has been completed. The results show statistically
significant improvement in the growth velocity in preterm infants
when Kiobrina(TM) was added to infant formula compared to placebo.
The safety profile was comparable to that of placebo and no drug
related serious adverse events were reported.

The study was a prospective randomized double-blind crossover study
where Kiobrina(TM), or placebo, was administered in preterm infant
formula during one week of treatment. All infants were born before
week 32 of gestational age. The next step in the establishment of
proof of concept is the completion of the second study where preterm
infants are treated with Kiobrina(TM) administrated in pasteurized
breast milk. Results from this second trial are expected in the
beginning of 2010.

"The initial Phase II clinical results in this high medical need
population are very encouraging. If the ongoing parallel study in
preterm infants fed with pasteurized breast milk is also positive, we
have proof of concept and will advance the program into a
registrational stage," said Martin Nicklasson, CEO of Biovitrum.

About Kiobrina
Kiobrina is a recombinant human bile-salt-stimulated lipase (rhBSSL)
developed by Biovitrum
for enzyme replacement therapy to improve growth and development in
preterm infants receiving pasteurized breast milk and/or formula. The
rationale for substitution of rhBSSL in pasteurized breast milk or
infant formula is to restore the natural lipase activity level that
is either lost on pasteurization or totally absent in formula.

About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
enhancement of lipid absorption. The company has revenues of
approximately SEK 1.2 billion and around 400 employees. The company
head office is located in Sweden and it is listed on the Stockholm
OMX Nordic Exchange. For more information please visit
www.biovitrum.com.


For more information please contact:

Biovitrum AB (publ)

Erik Kinnman, Vice President Investor Relations
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com

Martin Nicklasson, CEO
Phone. +46 8 697 2327



The clinical phase II studies has been carried out partially with
research funding from the European Community's Sixth Framework
Program (The Early Nutrition Programming Project,
www.metabolic-programming.org). The press release reflects only the
author's views and does not necessarily reflect the views of the
European Community or European Commission or their future policy,
and they are not liable for any use that may be made of the
information contained herein.  The information in this document is
provided as is and no guarantee or warranty is given that the
information is fit for any particular purpose. The user thereof uses
the information at its sole risk and liability.

Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on November 25, 2009 at
08:30 a.m. CET.